March 14th, 2011
AHA Offers Qualified Endorsement of Weight-Loss Surgery
Larry Husten, PHD
For the first time, the AHA has offered a qualified endorsement of bariatric surgery. The scientific statement, published in Circulation, states that bariatric surgery is a relatively safe procedure that can lead to long-term weight loss and significantly improve health in appropriately selected obese patients who have been unable to lose weight nonsurgically.
But, said Paul Poirier, the lead author of the statement, in an AHA press release, “it is not an across-the-board endorsement of bariatric surgery for the severely obese. It is a consensus document that provides expert perspective based on the results of recent scientific studies.”
The statement notes that surgical weight loss can “completely reverse established diabetes mellitus in a large percentage of subjects” and results in improvements in lipids, inflammation, nonalcoholic fatty liver disease, hypertension, sleep apnea, and cardiac function. The report states that “there is increasing, although not definitive, evidence that bariatric surgery provides a significant survival benefit.”
Categories: General, Prevention
Tags: bariatric surgery, obesity, weight loss
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “AHA Offers Qualified Endorsement of Weight-Loss Surgery”
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Last Man Running August 8, 2026As the health of his brother and running buddy rapidly declines and he faces his own health scares, a physician feels compelled — and grateful — to keep moving forward.
- Finerenone in Persons with Chronic Kidney Disease without Diabetes August 6, 2026In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months.
- Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD August 6, 2026In a patient with Duchenne muscular dystrophy, cardiotoxic effects developed after treatment with delandistrogene moxeparvovec. Microdystrophin levels in the heart and skeletal muscle were less than 1% of normal dystrophin levels.
- Mineralocorticoid Receptor Antagonism — FINDing Another Benefit August 6, 2026Aldosterone plays a critical role in the homeostasis of blood pressure and volume by engaging mineralocorticoid receptors in the kidneys, heart, and other organs.1 However, overactivation of mineralocorticoid receptors contributes to the pathogenesis of chronic kidney disease (CKD) and heart failure, in part by causing inflammation and fibrosis....
- Oxygen Targets after Cardiac Arrest — A LOGICAL Finding August 6, 2026In unresponsive patients after cardiac arrest, a complex pathophysiological response including potential brain injury, myocardial dysfunction, and systemic ischemia–reperfusion injury is at play, in addition to the challenges of the underlying cause of cardiac arrest.1 This complex and unique, but heterogeneous, constellation has prompted clinicians and researchers to...
- Last Man Running August 8, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women

There is no doubt that bariatric surgery is useful in morbidly obese, but the judicious selection of patients ,taking into account their personality profile is of the utmost importance.The so called “complete reversal of diabetes” is yet to be observed on a long term basis.
Competing interests pertaining specifically to this post, comment, or both:
none